Data for non-IBC metastatic HR+ breast cancer has demonstrated excellent efficacy of endocrine-based therapy in the 1st line setting allowing delay of chemotherapy until later lines. However, IBC behaves very differently than non-IBC and tends to be higher grade with more endocrine resistance. Given...